Gastrounit, Copenhagen University Hospital Hvidovre
Hvidovre, Copenhagen, 2650, Denmark
NCT Number: NCT04842149
The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with small intestinal Crohn's disease.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Hvidovre, Copenhagen, 2650, Denmark
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with an incidence rate at 11/100 000 per year in Denmark.
The disease can potentially affect the entire gastrointestinal tract, though the most common affected area is terminal ileum and the adjacent part of colon.
CD is a result of both genetic and environmental factors together with the intestinal microbiota, however the precise etiology is unclear.
A change of the intestinal microbiota with a reduced occurrence of e.g. Bacteroides species, Firmicutes and the anti-inflammatory bacteria Faecalibacterium prausnitzii is found in CD patients compared to healthy controls. Also a reduction of the mucosa-associated Bifidobacteria has been associated with the risk of mucosal inflammation.
The hypothesis that an imbalance between potentially beneficial and pathogenic bacteria contribute to the pathogenesis of IBD, including CD, has led to the suggestion that manipulation of the microbiota may be an attractive target for therapeutic interventions in IBD.
A new probiotic bacterium, Bifidobacterium breve Bif195 (Bif195) has been identified and has shown great effects on preventing enteropathy and ulcers on the gut mucosa in healthy volunteers given acetylsalicylic acid (13), and thereby Bif195 has also shown a potential in reducing gut permeability defects. This bacterium has not yet been investigated in CD patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 capsule daily for 8 weeks
1 capsule daily for 8 weeks
Time frame: 8 weeks
IUS will be performed in the non-fasting patient lying in supine position with a high-end ultrasound machine (Siemens Sequoia) with 10L4 transducer.
Time frame: 8 weeks
measured from a fecal sample
Time frame: 8 weeks
HBI is a disease activity index for Crohns disease and consists of clinical parameters
Time frame: 8 weeks
The IBDQ is a widely used instrument to assess QoL among IBD patients and consists of 32 questionaire
Time frame: 8 weeks
measured by intestinal ultrasound (IUS)
Time frame: 16 weeks
Registered, if any events. Reported according to IHC-GCP
Hvidovre University Hospital
Other
The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04673357
Crohn Disease, Digestive System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT05013905
Crohn Disease, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsNCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsNCT04245215
Crohn Disease, Digestive System Diseases
Zaventem, Belgium
View Trial Details